PepGen Beheer

Beheer criteriumcontroles 2/4

De CEO PepGen is James McArthur, benoemd in Jan2021, heeft een ambtstermijn van 3.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.43M, bestaande uit 16.7% salaris en 83.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.005% van de aandelen van het bedrijf, ter waarde $ 10.98K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.7 jaar en 3.3 jaar.

Belangrijke informatie

James McArthur

Algemeen directeur

US$3.4m

Totale compensatie

Percentage CEO-salaris	16.7%
Dienstverband CEO	3.8yrs
Eigendom CEO	0.005%
Management gemiddelde ambtstermijn	1.7yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans

Aug 06

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

Jul 31

Here's Why We're Not Too Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

Sep 07

PepGen GAAP EPS of -$1.23 misses by $0.47

Aug 12

Analyse CEO-vergoeding

Hoe is James McArthur's beloning veranderd ten opzichte van PepGen's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$89m
Mar 31 2024	n/a	n/a	-US$80m
Dec 31 2023	US$3m	US$572k	-US$79m
Sep 30 2023	n/a	n/a	-US$74m
Jun 30 2023	n/a	n/a	-US$69m
Mar 31 2023	n/a	n/a	-US$67m
Dec 31 2022	US$5m	US$523k	-US$69m
Sep 30 2022	n/a	n/a	-US$61m
Jun 30 2022	n/a	n/a	-US$51m
Mar 31 2022	n/a	n/a	-US$39m
Dec 31 2021	US$4m	US$408k	-US$27m

Compensatie versus markt: De totale vergoeding ($USD 3.43M ) James } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.48M ).

Compensatie versus inkomsten: De vergoeding van James is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

James McArthur (62 yo)

3.8yrs

Tenure

US$3,425,703

Compensatie

Dr. James G. McArthur, Ph D., serves as the President, Chief Executive Officer, Treasurer and Secretary of PepGen Inc. since January 21, 2021. He joined PepGen Inc. in January 2021.He serves as the Presid...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
James McArthur	President	3.8yrs	US$3.43m	0.0052% $ 11.0k
Noel Donnelly	Chief Financial Officer	3.1yrs	US$1.97m	0% $ 0
Michelle Mellion	Chief Medical Officer	2.6yrs	US$1.41m	0% $ 0
Michael Gait	Founder & Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
David Borah	Senior VP of IR & Corporate Communications	less than a year	geen gegevens	geen gegevens
Mary DeLena	General Counsel & Secretary	less than a year	geen gegevens	geen gegevens
Niels Svenstrup	Senior Vice President of Chemistry	3.6yrs	US$1.32m	0% $ 0
Emiko Bryant	Chief of Staff	less than a year	geen gegevens	geen gegevens
Hayley Parker	Senior Vice President of Global Regulatory Affairs	less than a year	geen gegevens	geen gegevens
Afsaneh Mohebbi	Senior VP of Portfolio and Program Management	less than a year	geen gegevens	geen gegevens
Kyle Breidenstine	VP of Finance & Controller	2.8yrs	geen gegevens	geen gegevens

1.7yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PEPG wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
James McArthur	President	3.8yrs	US$3.43m	0.0052% $ 11.0k
Michael Gait	Founder & Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Laurie Keating	Independent Chair of the Board	2.9yrs	US$154.82k	0.013% $ 27.0k
Arthur Krieg	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Heidi Henson	Independent Director	3.3yrs	US$123.32k	0% $ 0
Joshua Resnick	Independent Director	4yrs	US$111.32k	0% $ 0
Matthew Wood	Scientific Advisory Board Member	no data	US$85.25k	geen gegevens
Charles Thornton	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
John Day	Scientific Advisory Board Member	3.1yrs	geen gegevens	geen gegevens
Beth McNally	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Jonathan Watts	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Brenda Wong	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PEPG wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

PepGen Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

PepGen Inc. Announces Christopher Ashton to Retire from Its Board of Directors, Effective September 30, 2024

PepGen Inc. Appoints Paul Streck as Executive Vice President, Head of Research & Development, Head of Research & Development

Chief Medical Officer exercised options and sold US$61k worth of stock

Chief Medical Officer exercised options and sold US$72k worth of stock

PepGen Inc. Appoints Afsaneh Mohebbi as SVP, Portfolio and Program Management and Dave Borah as SVP, Investor Relations and Corporate Communications

Chief Medical Officer exercised options and sold US$74k worth of stock

Recent updates

PepGen Inc. Announces Christopher Ashton to Retire from Its Board of Directors, Effective September 30, 2024

New major risk - Share price stability

PepGen Inc. Appoints Paul Streck as Executive Vice President, Head of Research & Development, Head of Research & Development

Price target decreased by 9.3% to US$19.60

PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans

Chief Medical Officer exercised options and sold US$61k worth of stock

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

PepGen Inc. Announces Positive Data from Low-Dose Cohort of Pgn-Edo51 in Ongoing Connect1-Edo51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

Chief Medical Officer exercised options and sold US$72k worth of stock

PepGen Inc. Appoints Afsaneh Mohebbi as SVP, Portfolio and Program Management and Dave Borah as SVP, Investor Relations and Corporate Communications

Chief Medical Officer exercised options and sold US$74k worth of stock

Pepgen Inc. Announces Executive Promotions

Insider notifies of intention to sell stock

The Prognosis For PepGen

Senior Vice President of Chemistry notifies of intention to sell stock

PepGen Inc., Annual General Meeting, Jun 20, 2024

PepGen Inc., Annual General Meeting, Jun 20, 2024

PepGen Inc. Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Inc. Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1

PepGen Inc. has completed a Follow-on Equity Offering in the amount of $80.08155 million.

New minor risk - Shareholder dilution

New major risk - Share price stability

Price target decreased by 14% to US$20.00

PepGen: Long Road Ahead

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

Pepgen Inc. Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of P GN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping

Pepgen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

Pepgen Announces First Patient Dosed in Phase 1 Freedom-Dm1 Clinical Trial of Pgn-Edodm1 for Myotonic Dystrophy Type 1

PepGen Inc. Announces Appointment of Howard Mayer, M.D. to Board of Directors

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

New major risk - Revenue and earnings growth

PepGen Inc. Announces FDA Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company's Enhanced Delivery Oligonucleotide Platform and PGN-EDO Program at Two Medical Conferences

New major risk - Share price stability

New major risk - Revenue and earnings growth

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1

New major risk - Share price stability

Pepgen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate A Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1

PepGen Inc. to Report Q1, 2023 Results on May 11, 2023

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Key Executive notifies of intention to sell stock

We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth

PepGen Inc. Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies

High number of new and inexperienced directors

PepGen Inc. Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates

PepGen Inc. Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Appoints Habib Dable to Board of Directors

Here's Why We're Not Too Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

PepGen GAAP EPS of -$1.23 misses by $0.47

PepGen Inc. Appoints Caroline Godfrey to Its Scientific Advisory Board

PepGen Inc. has completed an IPO in the amount of $108 million.

High number of new and inexperienced directors

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd